MétaCan
Menu
← Back to cohort

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey

2025· dataset· en· W6958903643 on OpenAlexaboutno aff

Bibliographic record

VenueFigshare · 2025
Typedataset
Languageen
FieldAgricultural and Biological Sciences
TopicPlant pathogens and resistance mechanisms
Canadian institutionsnot available
Fundersnot available
KeywordsGenetic testingBreast cancerOvarian cancerBRCA mutationCancerBlood testingHomologous recombinationGenetic counseling

Abstract

fetched live from OpenAlex

To explore physician-reported knowledge, use, and perceptions of genetic testing for advanced ovarian cancer management. Gynecology/oncology specialists (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey spanning March 2021 to April 2022. Physician-reported breast cancer gene mutation (BRCAm) testing rates increased over the 2 years before the survey; most patients underwent testing in the preceding 6 months. Homologous recombination deficiency (HRD) genomic instability testing rates and physicians’ confidence interpreting results remained relatively low. Genetic testing was driven by the associated treatment implications of the findings. Poor performance status, inadequate tissue, and patients’ willingness to undergo testing were reported barriers to testing. Findings indicate that there is a need to improve both access to and information about HRD testing. Why did we perform this research? Testing for breast cancer gene mutations (BRCAm) is strongly recommended to guide treatment decisions for patients with ovarian cancer (OC), with screening for homologous recombination deficiency (HRD) genomic instability (when cells cannot accurately repair breaks in DNA strands) also recommended. However, not all eligible women are tested, indicating that a greater understanding of physicians’ testing practices is needed. What did we do? Physicians (n = 390) in the US, Europe, Canada, Japan, and Australia completed an online survey that evaluated their knowledge, use, and perceptions of genetic testing for advanced OC management. What were the results? Across all countries, physicians reported increasing BRCAm testing rates over the 2 years before the survey, with most patients with advanced OC now receiving these tests. HRD testing rates were relatively low, and few physicians reported complete confidence in interpreting these test results. Physicians most commonly reported that genetic testing was conducted because the results could guide treatment decisions. The main reasons for not conducting tests were patients being too unwell, tissue samples being inadequate, or patients being unwilling to undergo testing. Across countries, most physicians agreed genetic counseling should be offered to patients with OC; however, in some countries, there was insufficient access to these services. What are the implications? Our findings indicate that physicians’ understanding of the wider implications of genetic testing, including HRD testing, and patients’ access to genetic counseling may require improvement to ensure patients with advanced OC receive optimal care.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.010
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Dataset · Consensus signal: none
Teacher disagreement score0.025
Threshold uncertainty score0.049

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.010
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.264
Teacher spread0.225 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreDataset

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFigshare→Same topicPlant pathogens and resistance mechanisms→French-language works237,207→